Leading International Investment Research, Edison Investment Research

Edison Investment Research

Leading International Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Equity Bottom-Up

Basilea Pharmaceutica Ag / Equity Bottom-Up

<p>Basilea announced a hat trick of positive news flow in June. This includes two separate licensing deals covering Cresemba (for invasive mould infections) and Zevtera, as well as triggering the allocation of  $54.8m reimbursement funding from the Biomedical Advanced Research and Development Authority (BARDA) relating to the advancement of Zevtera&rsquo;s US phase III clinical programme for bacterial infections (trials to initiate H217). Most notable is the major licensing deal with Pfizer for Cresemba in Europe, Russia, Turkey and Israel; Pfizer is the partner of choice given its long-standing expertise in this market. Additionally, Avir Pharma has licensed both Cresemba and Zevtera for the Canadian market. Our forecasts and valuation are under review; we will update both post further disclosure on the PFE deal at the interim results on 10 August.</p>

Basilea announced a hat trick of positive news flow in June. This includes two separate licensing deals covering Cresemba (for invasive mould infections) and Zevtera, as well as triggering the allocation of  $54.8m reimbursement funding from the Biomedical Advanced Research and Development Authority (BARDA) relating to the advancement of Zevtera&rsquo;s US phase III clinical programme for bacterial infections (trials to initiate H217). Most notable is the major licensing deal with Pfizer for Cresemba in Europe, Russia, Turkey and Israel; Pfizer is the partner of choice given its long-standing expertise in this market. Additionally, Avir Pharma has licensed both Cresemba and Zevtera for the Canadian market. Our forecasts and valuation are under review; we will update both post further disclosure on the PFE deal at the interim results on 10 August.

<p>Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales in H216 combined with lower than expected operating costs. Cresemba (for invasive mould infections), in particular, continues to pick up momentum both in the EU and the US through US partner Astellas. Zevtera&rsquo;s US pivotal Phase III clinical trial programme for bacterial infections remains on track to initiate in mid-2017. Multiple distribution and commercialisation agreements signed in H216 should lead to international launches starting from 2018 for both products. We value Basilea at CHF1,048m or CHF97/share.</p>

Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales in H216 combined with lower than expected operating costs. Cresemba (for invasive mould infections), in particular, continues to pick up momentum both in the EU and the US through US partner Astellas. Zevtera&rsquo;s US pivotal Phase III clinical trial programme for bacterial infections remains on track to initiate in mid-2017. Multiple distribution and commercialisation agreements signed in H216 should lead to international launches starting from 2018 for both products. We value Basilea at CHF1,048m or CHF97/share.

Switzerland

Basilea Pharmaceutica AG operates as a biopharmaceutical company. The Company focuses on the research, development, and commercialization of products targeting the medical challenge of resistance and non-response to current treatment options for fungal infections, bacterial infections, and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Basilea Pharmaceutica Ag (BSLN SW)

Hat trick

Basilea announced a hat trick of positive news flow in June. This includes two separate licensing deals covering Cresemba (for invasive mould...

Edison Investment Research

Steady as she goes

Basilea reported a solid set of 2016 numbers ahead of guidance, driven by higher than expected product sales in H216 combined with lower than...

Edison Investment Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)